VivoSeq
Other

Tuvonralimab

0

Pipeline Programs↗

4

Active Trials↗

0

Companies Involved↗

Tuvonralimab is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Recruiting·—·Phase 2·NCT07232654·30 enrolled
Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC
Not yet recruiting·FFudan University·Phase 2·NCT07152769·104 enrolled
Iparomlimab and Tuvonralimab in HNSCC
Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT07090317·30 enrolled
Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors
Recruiting·PPeking Union Medical College Hospital·Phase 1/2·NCT06941766·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)